Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shelter PharmaBOM:543963 -2.26%66 Pretax Margin % is 15.59% as of Mar. 2026, which is 7% below its 10-year median of 16.72. GuruFocus rates BOM:543963 with a GF Score™ of 66/100 and a GF Value™ of ₹57.02 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 960 Drug Manufacturers companies, Shelter Pharma ranks better than 74.9% on this metric.
The historical rank and industry rank for Shelter Pharma's Pretax Margin % or its related term are showing as below:
BOM:543963'
s Pretax Margin % Range Over the Past 10 Years
Min: -1.06 Med: 16.72 Max: 20.69
Current: 16.72
BOM:543963's Pretax Margin % is ranked better than 74.9% of 960
companies
in the Drug Manufacturers industry
Industry Median: 7.045
vs BOM:543963: 16.72
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Shelter Pharma Pretax Margin % Related Terms
Shelter Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Shelter Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shelter Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shelter Pharma Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shelter Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Shelter Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shelter Pharma (BOM:543963) has a Pretax Margin % of 15.59% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Shelter Pharma and its competitors. This is near median its historical median of 16.72. According to the industry distribution chart, Shelter Pharma ranks #241 out of 960 companies in the Drug Manufacturers industry, placing it in the top 25.1%.
Is Shelter Pharma's Pretax Margin % too high?
Shelter Pharma's current Pretax Margin % of 15.59% is near median its 10-year median of 16.72. The Drug Manufacturers industry median Pretax Margin % is 7.05. Shelter Pharma's value of 15.59% is 121.3% above this industry median. Based on the distribution chart, Shelter Pharma ranks #241 out of 960 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shelter Pharma has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Shelter Pharma's Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shelter Pharma ranks #241 out of 960 companies for Pretax Margin %. This puts Shelter Pharma in the upper half of its industry. The industry median Pretax Margin % is 7.05. Shelter Pharma's value of 15.59% is 121.3% above this benchmark. While the company's 10-year median is 16.72 vs. the industry median of 7.05, Shelter Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.05, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shelter Pharma's current Pretax Margin % of 15.59% is 121.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Shelter Pharma and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shelter Pharma's current Pretax Margin % is 15.59%, which is near median its own 10-year median of 16.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shelter Pharma stock overvalued right now?
Based on GuruFocus' analysis, Shelter Pharma (BOM:543963) is currently considered Possible Value Trap. The stock's GF Value™ is ₹57.02, compared to a current price of ₹26.00 — trading 54.4% below its estimated fair value. The current Pretax Margin % is 15.59%, which is near median its 10-year median of 16.72 and 121.3% above the Drug Manufacturers industry median of 7.05. Shelter Pharma's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Shelter Pharma (BOM:543963), the current Pretax Margin % is 15.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shelter Pharma (BOM:543963) Overvalued in 2026?
Based on GuruFocus' analysis, Shelter Pharma stock appears to be undervalued.
The current stock price of ₹26.00 is trading 54.4% below its estimated GF Value™ of ₹57.02.
GuruFocus considers Shelter Pharma to be Possible Value Trap.
Key valuation signals for BOM:543963:
Pretax Margin %: 15.59% (near median its 10-year median of 16.72)
GF Value™: ₹57.02 vs. price of ₹26.00 (54.4% below fair value)
Industry Position: 121.3% above the Drug Manufacturers median (#241 of 960)
No single metric tells the full story. See the BOM:543963 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shelter Pharma Ltd focuses in manufacturing herbal products with a well-built presence in Human Pharma as well as the Veterinary space. It is present in majority of the non-critical segments of human and veterinary pharma through its well-spread portfolio. Its products include tablets, syrups, baby drops, barley water, oils, powders, ointments, etc.
66GF Score
Get the complete analysis for BOM:543963
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543963 has been successfully added to your 
